ClinicalTrials.gg
RecruitingNCT05683717Updated Nov 21, 2023

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

A Phase 1 interventional study of TT-01488 Tablets in B-Cell Malignancies, sponsored by TransThera Sciences (Nanjing), Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.

Read the detailed description

The study will consist of two parts, dose escalation and dose expansion. A modified 3+3 design will be used to guide the dose escalation and the determination of the dose recommended for dose expansion (DRDE). A sentinel cohort comprising of one subject will be enrolled at a starting dose of 50 mg q.d. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design to determine the DRDE. Once the DRDE has been selected, TT-01488 of DRDE will be further tested in the dose expansion cohort to verify the safety and preliminary efficacy as observed in the dose escalation cohorts. A recommended Phase II dose (RP2D) may be determined based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation cohorts and dose expansion cohort.

02

Conditions studied

  • B-Cell Malignancies
03

In context

Lead sponsor

TransThera Sciences (Nanjing), Inc. is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed B-cell , failed or intolerant to either ≥ 2 prior standard/common regimens given in combination or sequentially OR have received 1 prior BTK-containing regimen, relapse/, and with treatment indication:

    • CLL/SLL treated with prior immunochemistry or BTK inhibitor containing regimen;
    • DLBCL treated with prior CD20 or anthracyclines containing regimen;
    • Other types of B-cell NHL treated with prior CD20 containing regimen
  • Adequate organ function, defined by the following laboratory parameters:

    • Hematologic:
  • (ANC) ≥ 0.75×10\^9/L, and ≥ 0.5×10\^9/L if bone marrow involved
  • ≥ 50×10\^9/L without transfusion within 7 days, and ≥ 30×10\^9/L if bone marrow involved
  • ≥ 8.0 g/dL without transfusion within 7 days, and ≥ 7.0 g/dL if bone marrow involved

    • Coagulation:
  • (PT) ≤ 1.5 ×
  • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN

    • Renal function:
  • ≥ 30 mL/min estimated based on Cockcroft-Gault formula

    • Liver function:
  • Total ≤ 1.5 × ULN (unless due to Gilbert's disease)
  • (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN unless disease-related

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years or which will not limit survival to \< 2 years (Note: these cases must be discussed with the Medical Monitor and/or Investigator)
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or significant screening abnormalities
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  • History of or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of the following:

    • Active (GvHD);
    • Cytopenias from incomplete blood cell count recovery post-transplant;
    • Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy;
    • Ongoing therapy
  • Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Dose Escalation for TT-01488

    TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.

    Drug: TT-01488 Tablets

  • Experimental
    Dose Expansion for TT-01488

    TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.

    Drug: TT-01488 Tablets

Interventions

  • TT-01488 tablet will be administered orally once daily per protocol defined schedule.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT) of TT-01488

    Safety and tolerability of TT-01488 as a single agent

    Time frame: Up to 28 days after first dose

  2. Dose recommend for dose expansion (DRDE)

    Safety and tolerability of TT-01488 as a single agent

    Time frame: 3 years

  3. Maximum Tolerated Dose (MTD), if reached, of TT-01488

    Safety and tolerability of TT-01488 as a single agent

    Time frame: Up to 28 days after first dose

Secondary outcomes

  1. Number of participants with treatment-related adverse events (AEs)

    Safety and tolerability of TT-01488 as a single agent. AEs will be assessed per CTCAE v5.0 or 2018 IWCLL and may include, but is not limited to, clinically abnormal laboratory tests, physical exams, vital signs, electrocardiograms, and ECOG performance status.

    Time frame: 3 years

  2. Area under the concentration time curve (AUC 0-t)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  3. Maximum plasma concentration (Cmax)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  4. Time to Maximum Plasma Concentration (Tmax)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  5. Half-life (T1/2)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  6. Mean Residence Time (MRT)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  7. Apparent volume of distribution associated with the terminal phase (Vz/F)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  8. Apparent clearance (CL/F)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 3 years

  9. Objective Response Rate (ORR)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 3 years

  10. Disease Control Rate (DCR)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 3 years

  11. Duration of Response (DOR)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 3 years

  12. Progression free survival (PFS)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 3 years

  13. Overall survival (OS)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Oct 2026, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 13, 2023
StartActual
Mar 30, 2023
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 30, 2028
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05683717
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Mar 30, 2023
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Nov 21, 2023

Study contacts

Sun Caixia, PhD
Contact
clinicaltrial@transtherabio.com
025-58216298
Li Jianyong
principal investigator · The First Affiliated Hospital with Nanjing Medical University
Xu Wei
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor TT-01488

Start the discussion